{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:11:26Z","timestamp":1789823486363,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.heliyon.2024.e38839","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T23:21:31Z","timestamp":1727824891000},"page":"e38839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Small intestinal metastasis in a lung adenocarcinoma patient with concurrent EML4-ALK V3 and TP53 mutations after distinct responses to tyrosine kinase inhibitors: A case report"],"prefix":"10.1016","volume":"10","author":[{"given":"Lingling","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengxu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3745-9539","authenticated-orcid":false,"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2024.e38839_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca - Cancer J. Clin."},{"issue":"10299","key":"10.1016\/j.heliyon.2024.e38839_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e38839_bib3","first-page":"51","article-title":"Is gastrointestinal metastasis of primary lung malignancy as rare as reported in the literature? A comparison between clinical cases and post-mortem studies","volume":"12","author":"Jevremovic","year":"2016","journal-title":"Oncology & Hematology Review (US)"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38839_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0169-5002(99)00075-6","article-title":"Small bowel metastases in non-small cell lung cancer","volume":"26","author":"Stenbygaard","year":"1999","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38839_bib5","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.3892\/ol.2017.6382","article-title":"Analysis of gastrointestinal metastasis of primary lung cancer: clinical characteristics and prognosis","volume":"14","author":"Taira","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.heliyon.2024.e38839_bib6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.critrevonc.2017.12.015","article-title":"Precision medicine in ALK rearranged NSCLC: a rapidly evolving scenario","volume":"122","author":"Addeo","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38839_bib7","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38839_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4143\/crt.2021.1571","article-title":"Efficacy and safety of ceritinib 450 mg\/day with food and 750 mg\/day in fasted state in treatment-na\u00efve patients with ALK+ non-small cell lung cancer: results from the ASCEND-8 asian subgroup analysis","volume":"55","author":"Cho","year":"2023","journal-title":"Cancer Res Treat."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38839_bib9","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38839_bib10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.cllc.2022.07.008","article-title":"Efficacy and safety of brigatinib compared with crizotinib in asian vs. Non-asian patients with locally advanced or metastatic ALK-inhibitor-naive ALK+ non-small cell lung cancer: final results from the phase III ALTA-1L study","volume":"23","author":"Ahn","year":"2022","journal-title":"Clin. Lung Cancer"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38839_bib11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2022.02.014","article-title":"Lorlatinib for previously treated ALK-positive advanced NSCLC: primary efficacy and safety from a phase 2 study in people's Republic of China","volume":"17","author":"Lu","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38839_bib12","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1016\/j.jtho.2021.01.155","article-title":"FP14.12 quality of life and subgroup analysis in a phase 3 randomized study of ensartinib vs crizotinib in ALK\u2013positive NSCLC patients: eXalt3","volume":"16","author":"Selvaggi","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.heliyon.2024.e38839_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2021.06.012","article-title":"Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC","volume":"158","author":"Zhang","year":"2021","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38839_bib14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","article-title":"Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis","volume":"20","author":"Qin","year":"2020","journal-title":"BMC Cancer"},{"issue":"33","key":"10.1016\/j.heliyon.2024.e38839_bib15","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.18632\/oncotarget.26886","article-title":"Defining molecular risk in ALK(+) NSCLC","volume":"10","author":"Christopoulos","year":"2019","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38839_bib16","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1177\/1078155220904133","article-title":"Synchronous duodenum and descending colon metastasis from primary lung neuroendocrine small-cell carcinoma: a case report and review of the literature","volume":"26","author":"Tanriverdi","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e38839_bib17","doi-asserted-by":"crossref","first-page":"C134","DOI":"10.4103\/0973-1482.163873","article-title":"Undiagnosed primary lung carcinoma with initial manifestation of intestinal obstruction: a case report and literature review","volume":"11","author":"Chen","year":"2015","journal-title":"J. Cancer Res. Therapeut."},{"issue":"Suppl","key":"10.1016\/j.heliyon.2024.e38839_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.5761\/atcs.cr.13-00099","article-title":"Intussusception caused by intestinal metastasis from lung pleomorphic carcinoma","volume":"20","author":"Lin","year":"2014","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.heliyon.2024.e38839_bib19","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.2147\/OTT.S178985","article-title":"Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib","volume":"11","author":"Chen","year":"2018","journal-title":"OncoTargets Ther."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38839_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1556-0864(15)30037-X","article-title":"Primary lung cancer presenting with gastrointestinal tract involvement: clinicopathologic and immunohistochemical features in a series of 18 consecutive cases","volume":"2","author":"Rossi","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"26","key":"10.1016\/j.heliyon.2024.e38839_bib21","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e38839_bib22","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38839_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/path.4950","article-title":"Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer","volume":"243","author":"Noh","year":"2017","journal-title":"J. Pathol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38839_bib24","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","article-title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","volume":"29","author":"Kron","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38839_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010124","article-title":"Detection of TP53 mutations in tissue or liquid rebiopsies at progression identifies ALK+ lung cancer patients with poor survival","volume":"11","author":"Christopoulos","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e38839_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920980558","article-title":"Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program","volume":"13","author":"Frost","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e38839_bib27","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38839_bib28","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jtho.2020.02.007","article-title":"Detection of nonreciprocal\/reciprocal ALK translocation as poor predictive marker in patients with first-line crizotinib-treated ALK-rearranged NSCLC","volume":"15","author":"Zhang","year":"2020","journal-title":"J. Thorac. Oncol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024148700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024148700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:38:12Z","timestamp":1789821492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024148700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":28,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2405844024148700"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38839","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small intestinal metastasis in a lung adenocarcinoma patient with concurrent EML4-ALK V3 and TP53 mutations after distinct responses to tyrosine kinase inhibitors: A case report","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e38839"}}